Literature DB >> 12874085

Low-dose angiotensin II enhances pressor responses without causing sustained hypertension.

Laura I Pelaez1, Melissa C Manriquez, Karl A Nath, Juan C Romero, Luis A Juncos.   

Abstract

Subpressor doses of angiotensin II (SP-Ang II) cause a slow increase in blood pressure in rats as assessed by tail cuff plethysmography (TCP), reflecting either sustained hypertension or an exaggerated pressor response to diverse stimuli. We examined whether subpressor doses of Ang II enhance blood pressure responses to simple stress (handling of trained rats for TCP). We implanted telemetry in Sprague-Dawley rats. After 10 days of recovery and TCP training, we implanted osmotic minipumps with either SP-Ang II (50 ng/kg per minute) or vehicle, and then measured systolic blood pressure continuously in unrestrained rats for 13 days. We also recorded telemetry readings while obtaining TCP measurements every 2 days. SP-Ang II increased blood pressure from 134+/-19 to 159+/-22 mm Hg by TCP, which matched the simultaneous telemetry readings of 131+/-20 to 154+/-25 mm Hg. In contrast, SP-Ang II did not change the blood pressure in the unrestrained rats (measured with continuous telemetry: 124+/-2 versus 127+/-1 mm Hg). The blood pressure in the control rats did not change in the unrestrained state (125+/-3 versus 128+/-5 mm Hg on days 0 and 12, respectively), and only slightly increased during TCP (11+/-5 and 6+/-4 mm Hg by TCP and simultaneous telemetry, respectively; P=NS). In summary, SP-Ang II, although unable to provoke sustained hypertension, nonetheless magnifies the pressor response to otherwise trivial stimuli. We speculate that even modestly elevated Ang II levels may contribute to hypertensive complications because such levels promote the punctuation of an apparent normotensive state by episodic hypertension occasioned by seemingly innocuous stimuli.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874085     DOI: 10.1161/01.HYP.0000085782.99773.B6

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Effects of captopril on the renin angiotensin system, oxidative stress, and endothelin in normal and hypertensive rats.

Authors:  Rodney J Bolterman; Melissa C Manriquez; M Clara Ortiz Ruiz; Luis A Juncos; J Carlos Romero
Journal:  Hypertension       Date:  2005-08-08       Impact factor: 10.190

2.  Heme oxygenase activity as a determinant of the renal hemodynamic response to low-dose ANG II.

Authors:  Karl A Nath; Melissa C Hernandez; Anthony J Croatt; Zvonimir S Katusic; Luis A Juncos
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-08-11       Impact factor: 3.619

Review 3.  Dietary fructose and hypertension.

Authors:  Magdalena Madero; Santos E Perez-Pozo; Diana Jalal; Richard J Johnson; Laura G Sánchez-Lozada
Journal:  Curr Hypertens Rep       Date:  2011-02       Impact factor: 5.369

Review 4.  Is the fructose index more relevant with regards to cardiovascular disease than the glycemic index?

Authors:  Mark S Segal; Elizabeth Gollub; Richard J Johnson
Journal:  Eur J Nutr       Date:  2007-09-01       Impact factor: 5.614

5.  Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability.

Authors:  Joanna A Phipps; Allen C Clermont; Sukanto Sinha; Tamie J Chilcote; Sven-Erik Bursell; Edward P Feener
Journal:  Hypertension       Date:  2009-01-05       Impact factor: 10.190

6.  The Modulatory Role of Heme Oxygenase on Subpressor Angiotensin II-Induced Hypertension and Renal Injury.

Authors:  Kiran Chandrashekar; Arnaldo Lopez-Ruiz; Ramiro Juncos; Karl Nath; David E Stec; Trinity Vera; Ruisheng Liu; Luis A Juncos
Journal:  Int J Hypertens       Date:  2012-03-11       Impact factor: 2.420

7.  Monitoring of Cardiorespiratory Parameters in Rats-Validation Based on Pharmacological Stimulation.

Authors:  Joanna Miklosz; Bartlomiej Kalaska; Stanislaw Zajaczkowski; Dariusz Pawlak; Andrzej Mogielnicki
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.